Cargando…
Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specifi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628692/ https://www.ncbi.nlm.nih.gov/pubmed/36319065 http://dx.doi.org/10.1136/jitc-2022-005577 |
_version_ | 1784823242473603072 |
---|---|
author | Haroun-Izquierdo, Alvaro Vincenti, Marianna Netskar, Herman van Ooijen, Hanna Zhang, Bin Bendzick, Laura Kanaya, Minoru Momayyezi, Pouria Li, Shuo Wiiger, Merete Thune Hoel, Hanna Julie Krokeide, Silje Zandstra Kremer, Veronika Tjonnfjord, Geir Berggren, Stéphanie Wikström, Kristina Blomberg, Pontus Alici, Evren Felices, Martin Önfelt, Björn Höglund, Petter Valamehr, Bahram Ljunggren, Hans-Gustaf Björklund, Andreas Hammer, Quirin Kveberg, Lise Cichocki, Frank Miller, Jeffrey S Malmberg, Karl-Johan Sohlberg, Ebba |
author_facet | Haroun-Izquierdo, Alvaro Vincenti, Marianna Netskar, Herman van Ooijen, Hanna Zhang, Bin Bendzick, Laura Kanaya, Minoru Momayyezi, Pouria Li, Shuo Wiiger, Merete Thune Hoel, Hanna Julie Krokeide, Silje Zandstra Kremer, Veronika Tjonnfjord, Geir Berggren, Stéphanie Wikström, Kristina Blomberg, Pontus Alici, Evren Felices, Martin Önfelt, Björn Höglund, Petter Valamehr, Bahram Ljunggren, Hans-Gustaf Björklund, Andreas Hammer, Quirin Kveberg, Lise Cichocki, Frank Miller, Jeffrey S Malmberg, Karl-Johan Sohlberg, Ebba |
author_sort | Haroun-Izquierdo, Alvaro |
collection | PubMed |
description | BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)(+)NKG2C(+) adaptive NK cells to maximize missing-self reactivity. METHODS: We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. RESULTS: ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45(dim) blast subtypes. CONCLUSIONS: These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability. |
format | Online Article Text |
id | pubmed-9628692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-96286922022-11-03 Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia Haroun-Izquierdo, Alvaro Vincenti, Marianna Netskar, Herman van Ooijen, Hanna Zhang, Bin Bendzick, Laura Kanaya, Minoru Momayyezi, Pouria Li, Shuo Wiiger, Merete Thune Hoel, Hanna Julie Krokeide, Silje Zandstra Kremer, Veronika Tjonnfjord, Geir Berggren, Stéphanie Wikström, Kristina Blomberg, Pontus Alici, Evren Felices, Martin Önfelt, Björn Höglund, Petter Valamehr, Bahram Ljunggren, Hans-Gustaf Björklund, Andreas Hammer, Quirin Kveberg, Lise Cichocki, Frank Miller, Jeffrey S Malmberg, Karl-Johan Sohlberg, Ebba J Immunother Cancer Immune Cell Therapies and Immune Cell Engineering BACKGROUND: Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)(+)NKG2C(+) adaptive NK cells to maximize missing-self reactivity. METHODS: We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML. RESULTS: ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45(dim) blast subtypes. CONCLUSIONS: These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability. BMJ Publishing Group 2022-11-01 /pmc/articles/PMC9628692/ /pubmed/36319065 http://dx.doi.org/10.1136/jitc-2022-005577 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Immune Cell Therapies and Immune Cell Engineering Haroun-Izquierdo, Alvaro Vincenti, Marianna Netskar, Herman van Ooijen, Hanna Zhang, Bin Bendzick, Laura Kanaya, Minoru Momayyezi, Pouria Li, Shuo Wiiger, Merete Thune Hoel, Hanna Julie Krokeide, Silje Zandstra Kremer, Veronika Tjonnfjord, Geir Berggren, Stéphanie Wikström, Kristina Blomberg, Pontus Alici, Evren Felices, Martin Önfelt, Björn Höglund, Petter Valamehr, Bahram Ljunggren, Hans-Gustaf Björklund, Andreas Hammer, Quirin Kveberg, Lise Cichocki, Frank Miller, Jeffrey S Malmberg, Karl-Johan Sohlberg, Ebba Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title | Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title_full | Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title_fullStr | Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title_full_unstemmed | Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title_short | Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia |
title_sort | adaptive single-kir(+)nkg2c(+) nk cells expanded from select superdonors show potent missing-self reactivity and efficiently control hla-mismatched acute myeloid leukemia |
topic | Immune Cell Therapies and Immune Cell Engineering |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628692/ https://www.ncbi.nlm.nih.gov/pubmed/36319065 http://dx.doi.org/10.1136/jitc-2022-005577 |
work_keys_str_mv | AT harounizquierdoalvaro adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT vincentimarianna adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT netskarherman adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT vanooijenhanna adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT zhangbin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT bendzicklaura adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT kanayaminoru adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT momayyezipouria adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT lishuo adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT wiigermeretethune adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT hoelhannajulie adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT krokeidesiljezandstra adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT kremerveronika adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT tjonnfjordgeir adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT berggrenstephanie adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT wikstromkristina adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT blombergpontus adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT alicievren adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT felicesmartin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT onfeltbjorn adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT hoglundpetter adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT valamehrbahram adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT ljunggrenhansgustaf adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT bjorklundandreas adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT hammerquirin adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT kveberglise adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT cichockifrank adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT millerjeffreys adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT malmbergkarljohan adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia AT sohlbergebba adaptivesinglekirnkg2cnkcellsexpandedfromselectsuperdonorsshowpotentmissingselfreactivityandefficientlycontrolhlamismatchedacutemyeloidleukemia |